This finding also suggests that repurposing MPO into quasi-catalase (cycle 5 of Figure 7), making KYC a systems pharmacology agent, is the primary mechanism for KYC’s many layers of protection against BPD. The gene discussed is MPO; the disease is bronchopulmonary dysplasia.